Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Safety and Feasibility Study of Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in Resectable Stage 3A Non-Small Cell Lung Cancer

NCT02987998 is registered in ClinicalTrials.gov with Nathan Pennell, MD, PhD as lead sponsor.

NCT NCT02987998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02987998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Safety and Feasibility Study of Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in Resectable Stage 3A Non-Small Cell Lung Cancer
Lead sponsor
Nathan Pennell, MD, PhD
Phase
Phase 1
Overall status
Terminated
Start date
May 19, 2017
Completion date
November 28, 2022
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iiia non-small cell lung cancer